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ABSTRACT
BACKGROUND: Alzheimer's disease (AD) has the potential to become a major
health concern and associated health care costs may become a significant economic
burden on society.
OBJECTIVE: The aim of this study was to estimate the direct medical costs at-
tributable to AD in patients aged ::0-60 years in Taiwan from 2000 through 2002 and
to explore the correlation of these costs with patients' age and sex.
METHODS: This study was based on the National Health Insurance Research
Database of Taiwan's National Health Insurance (NHI) program. The NHI program
insures >98% of the 23 million inhabitants of Taiwan. Detailed data were extracted
from a random sample of 0.2% of inpatient and 5% of outpatient recipients with AD
(International Classification 0/ Diseases, Ninth Revision, Clinical Modification diagnosis
code 331.0) who were aged ::0-60 years and who received inpatient or outpatient ser-
vices with claims from January 1,2000, to December 31, 2002. Duplicate charges for
a specific patient and diagnoses of other types of dementia were excluded from this
study.
RESULTS: A total of 69,780 patients were found to have a diagnosis of AD. The
direct medical costs for outpatients were estimated at US $1.2 million in 2000, US
$1.9 million in 2001, and US $2.3 million in 2002; the costs for inpatient care were
estimated at US $670,000 in 2000, US $2.4 million in 2001, and US $3.2 million in
2002. The total direct medical costs were estimated at US $1.86 million in 2000, US
$4.24 million in 2001, and US $5.48 million in 2002. The increase of total direct
medical costs was not significantly correlated with patients' age or sex.
CONCLUSIONS: From 2000 through 2002, the direct medical costs of AD in-
creased annually in Taiwan among patients with AD aged ::0-60 years. No significant
correlation was found between increased total direct medical costs and sex or age. The
cost estimate presented here has implications for future decision making about real-
locating medical resources for treating AD in Taiwan. (Curr Ther Res Clin Exp. 2009;
70:10-18) © 2009 Excerpta Medica Inc.
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INTRODUCTION
The prevalence of Alzheimer's disease (AD) in persons aged ::0-65 years has been esti-
mated to be 2% to 10% in the United States and 3.3% to 6.0% in Europe. 1 In east
Asia, the prevalence of AD has been estimated to be ~4.8% in China,2 2.1% in
Japan,3 and 2% to 4% in Taiwan. 4- 7 The number of people with AD in these coun-
tries is increasing gradually as the population ages. s AD has the potential to become
a major health concern and associated health care costs may become a significant bur-
den worldwide. The estimate of the worldwide direct costs of AD and dementia care
was increased from US $156 billion in 2003 9 to US $315 billion in 2005 10 annually
and is projected to nearly double by 2025 to 600 billion.7,10
Care of individuals with AD and dementia consists of formal and informal care.
The patterns of care differ throughout the world because of differences in cultures,
families, care organizations, and financing. Some researchers assumed that 73% of
people with dementia in developed countries lived at home and received 1.6 hours per
day of informal care to assist with the personal activities of daily life. 10 However, de-
termining the cost of informal care is a controversial and complicated issue. 1o
In Taiwan, as in many other countries, families are the main caregivers to older AD
patients who are no longer able to care for themselves. ll Such individuals usually re-
quire constant supportive care at home or in a nursing home (informal care) to im-
prove their basic and instrumental activities of daily living and medical treatment
(formal care).12 The costs of formal and informal care in patients with AD are high
and are related to disease severity and the presence of behavioral disturbances. 13- 15
A pilot study in Taiwan concluded that families with higher accessibility to nursing
homes were willing to pay US $174 per month more than caregivers with lower ac-
cessibility.16 Family caregivers who are aged> 65 years, have more than a high school
education, have a higher family income, and have easy accessibility to nursing home
services were likely to attach higher economic value to nursing home placement.
The economic and social burden of AD may become a major health care problem
in Taiwan. However, to date, research analyzing the costs of AD in Taiwan has not
been published.
This is the first pilot study to assess the direct medical costs of AD in Taiwan to
provide the National Health Insurance (NHI) program with economic data needed to
make decisions about reallocating medical resources and establishing preventive care
for the aging population.
METHODS
DATA SOURCE
Institutional review board approval was not required for this study because all
personal data were kept confidential by the NHI.
This study used a top-down approach based on the National Health Insurance
Research Database (NHIRD) of Taiwan's NHI program. Data were extracted from a
random sample of 0.2% inpatient and 5% outpatient insurance recipients with a di-
agnosis of AD (International Classification ofDiseases, Ninth Revision, Clinical Modifica-
tion [ICD-9-CM} diagnosis code 331.0).17 The sampling percentages were determined
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by the NHI, which also performed the randomization. The data files contain an origi-
nal system for sampling claims data, including monthly claim summaries for inpa-
tient claims, ambulatory care claims, inpatient expenditures by admissions, details
of inpatient orders, ambulatory care expenditures by visits, details of ambulatory
care orders, the primary diagnosis, up to 2 secondary diagnoses (in ICD-9-CM for-
mat), and a registry for beneficiaries. The registration file includes a registry for medi-
cal services and a registry for drug prescriptions. 1s
The NHI program is a comprehensive program that insures >98% of the 23 mil-
lion inhabitants of Taiwan. The NHIRD data are based on date of payment rather
than date of service. The 2000 to 2001 paid claims files were used to create a 1-year
file of claims for services provided during 2000; a similar procedure was used for 2001
and 2002 data. Payment for services provided is usually made within 3 months.
Therefore, using 1 year of paid claims to create a 1-year file of services would have
captured almost all relevant claims. Recipients who had invalid registry data were ex-
cluded from this study.
The components of direct medical costs include costs of medications and laboratory
tests, physicians' fees, pharmacist dispensing fees, room charges, meal service charges,
diagnosis examination charges (eg, computed tomography, magnetic resonance imag-
ing, single-photon emission computed tomography, positron emission tomography),
supportive treatment charges (eg, psychotherapy), and rehabilitation charges. Total
costs were indicated in US dollars using an exchange rate of Taiwan $I = US $32.80.
ALZHEIMER'S DISEASE COHORT SELECTION
All NHI recipients who were eligible for ::0-1 day during 2000 and who had only
1 medical claim (NHI does not allow duplicate claims) within 90 days in that year with a
primary or secondary diagnosis of AD were included. Diagnoses ofother types of dementia
(ICD-9-CM codes 290.0, 290.1, 290.10-290.13, 290.2, 290.20, 290.21, 290.3, 290.4,
290.40-290.43, 290.9, 294.9, 332.2, 331.89, 331.9, and 797) and possible duplicate
charges for a specific patient within 90 days were also excluded from this study.
STUDY MEASURES
Our study was focused on the direct medical costs to the NHI program from 2000
to 2002 for patient care. The direct medical costs for patients with the primary or
secondary diagnosis of AD were calculated.
STATISTICAL ANALYSIS
Descriptive analyses were conducted for the study cohort of patients with AD, in-
cluding demographic characteristics, NHI care eligibility status, and months ofNHI
care eligibility during 2000. The analyses were intended to describe the characteris-
tics of the AD cohort and to identifY whether age and sex might influence direct
medical costs.
The differences between total direct medical costs with patients' age and sex were
evaluated using the X2 test. The correlation between the increase in total direct medi-
cal costs and patients' age and sex were analyzed using Pearson correlation analysis.
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RESULTS
A total of 69,780 patients who were aged ::0-60 years with an ICD-9-CM code of 331.0
noted as the primary or secondary diagnosis from 2000 to 2002 in the inpatient and
outpatient claims file samples remained after we removed invalid claims, duplicate
claims within 3 months in the same year, and persons with an invalid date of birth.
Table I shows that 14.57% of patients were aged ::0-80 years, 1.36% were aged 60 to
69 years, 4.38% were aged 70 to 79 years, and 0.0008% were aged <;59 years. There
were more female patients than male patients in both the outpatient and inpatient
services (data not shown).
The direct medical costs for outpatients were estimated at US $1.2 million in 2000,
US $1.9 million in 2001, and US $2.3 million in 2002; the costs for inpatient care
were estimated at US $670,000 in 2000, US $2.4 million in 2001, and US $3.2 mil-
lion in 2002. The total direct medical costs for patients with a diagnosis of AD
were estimated to be US $1.86 million in 2000, US $4.24 million in 2001, and US
$5.48 million in 2002, which were ~0.02%, 0.05%, and 0.05% of the total health care
expenditures in Taiwan, respectively (Table II). Expenditures for inpatient and out-
patient services increased annually from 2000 to 2002. Mean annual cost per patient
was US $1418 in 2000, US $3793 in 2001, and US $5005 in 2002. The increase in
inpatient cost in 2000 was ~3.5-fold of that reported in 2001 (Tables III and IV).
The cost of medications accounted for 39.4%, 34.4%, and 33.7% of the total direct
medical costs claimed in 2000, 2001, and 2002, respectively (Table II).
Based on our estimate of total direct medical costs, annual spending by the NHI
program for AD is projected to be approximately US $105 million.
The correlation between the increases in total direct medical costs and age was not
significant; no linear relationship was found. Similarly, the correlation between total
direct medical costs and sex was not significant.
DISCUSSION
In this pilot study, we estimated the direct medical costs of AD and its correlation
with patient sex and the increasing age of the population in Taiwan. Results suggest
that the number of women aged> 75 years with AD was higher than that of men at
the same age. This result is consistent with some local and Western studies that found
that the prevalence of AD was higher in women than men, but the increase in inci-
dence remains a controversial issue.4 ,7,19,20 The age-adjusted incidence has been found
to be higher in women, particularly with advancing age.
The total direct medical costs for inpatient and outpatient care increased each year,
with the increase being higher for inpatient than outpatient costs. The reason for this
discrepancy might be that, in the early stages of AD, patients in Taiwan are generally
unaware of their condition and remain at home until the disease becomes more severe
and medical treatment is then sought. These results are consistent with the findings
of Meek et al21 that US patients are typically hospitalized in the later stages of AD,
resulting in a greater proportion of direct costs for inpatient care.
We found that the total direct medical costs and mean annual cost per patient
increased from 2000 to 2002. This may be related to physicians using the ICD-9-CM
13
Table I. Characteristics of patients in Taiwan with Alzheimer's disease.
:0;59 Years 60-69 Years
Male Female Male Female
Year SG B* SG B* SG B* SG B*
2000 500 9,349,760 0 9,398,296 1020 693,502 3040 713,519
2001 520 9,419,945 20 9,506,836 2020 694,596 3560 732,106
2002 0 9,497,868 0 9,582,575 2520 696,655 1020 745,486
Total 1020 28,267,573 20 28,487,707 5560 2,084,753 7620 2,191,111
% of B 0.0007 0.0001 0.53 0.83
70-79 Years ~80 Years
Male Female Male Female Total
Year SG B* SG B* SG B* SG B* SG B*
2000 2620 528,131 5140 424,644 1620 138,687 2560 154,287 16,500 21,400,826
2001 3640 539,650 6080 442,545 5200 151,643 2600 166,234 23,640 21,653,555
2002 6180 545,541 7600 458,107 5220 165,147 7100 178,099 29,640 43,054,381
Total 12,440 1,613,322 18,820 1,325,296 12,040 455,477 12,260 498,620 60,780 86,108,762
% of B 1.54 2.84 5.28 4.91 0.15
SG = study group; B = beneficiaries.
*Bureau of National Health Insurance, Taiwan.
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Table II. Changes in direct medical costs (US $) associated with Alzheimer's disease in Taiwan claimed from 2000 through
2002.
Total Health % of Total Medication
Expenditures Direct Medical Costs Claimed Health Care Portion of
Claimed Expend itu res Medication Medical Costs
Year (US $ Billion) Outpatient Inpatient Total Claimed Expenses Claimed, %
2000 9.0 1,190,584.60 672,474.50 1,863,059.10 0.02 734,193 39.4
2001 9.4 1,867,184.60 2,375,273.20 4,242,457.80 0.05 1,459,028 34.4
2002 10.3 2,330,369.20 3,151,787.70 5,482,156.90 0.05 1,848,386 33.7
Total 28.7 5,388,138.50 6,199,535.40 11,587,673.00 0.04 4,041,607 34.9
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Table III. Total direct medical costs (US $) associated with Alzheimer's disease for out-
patient care in Taiwan.
Year
2000
2001
2002
Total
No. of Patients
16,000
23,000
29,000
68,000
Total Direct Medical Cost
1,190,584.60
1,867,184.60
2,330,369.20
5,388,138.40
Mean (SO)
5445.90 (5325.90)
5984.00 (3976.80)
6384.70 (5933.60)
Table IV. Total direct medical costs (US $) associated with Alzheimer's disease for in-
patient care in Taiwan.
Year No. of Patients Total Direct Medical Cost Mean (SO)
2000 500 672,474.50 104,514.20 (67,758.70)
2001 640 2,375,273.20 333,571.50 (390,811.70)
2002 640 3,151,787.70 534,967.60 (567,473.20)
Total 1780 6,199,535.40
code for AD more accurately or to annual economic inflation. Compared with other
countries, the annual direct medical cost per patient reported in the United States
was US $7929,22 US $3420 to US $9658 in Argentina,23 US $1766 in Turkey, 1 and
US $1058 in China.24 The costs found in our study were lower than those reported in
the Western countries, but higher than the costs in China.
Another variable, medication costs, is also associated with direct medical costs.
More than 30% of the total direct medical costs for the treatment of AD were for
drugs. This finding is lower than the finding in a previous study in which drug costs
accounted for 36.0% of total direct medical costs in patients in the early stages of
AD22 and an average of 66.0% in patients at all stages of the disease. 1 This may be
due to a policy that restricts the global medication budget (the amount is determined
by the individual hospital's global budget issued by the Bureau of National Health
Insurance in Taiwan).18
The correlation between the increases in total direct medical cost with age and sex of
the population was small and no linear relationship was found in our study. However,
the effects of age and sex remain of concern in AD, as indicated by the findings of
2 studies conducted in southern Taiwan: one study found age to be a major risk factor
for AD4 and the other found that being of female sex was probably an AD risk factor. 19
LIMITATIONS
This study was subject to several limitations that are inherent in investigations that
rely on the use of health insurance claims data. 25,26 Patients may have been coded with
a diagnosis of AD while in fact they had another form of dementia. Similarly, some
patients may have been miscoded as having other forms of dementia that were excluded
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from the study. In addition, patients in the early stages of AD, when it is difficult to
diagnose, may not have had this diagnosis recorded on the claims files and thus would
not have been included in this study. In this pilot study, we did not control for differ-
ences in other covariants (eg, major chronic comorbid conditions, other prevalent
conditions). Therefore, disease prevalence and costs may have been underestimated.
Another limitation of this study was the lack of NHIRD data for disease severity.
Consequently, we were unable to estimate the effects of the severity of AD on costs.
Therefore, the standard errors of these estimates were large and the coefficients were
not statistically significant. The inability to separate AD costs from other costs in AD
patients was also a limitation of the study.
The increasing number of elderly people poses a challenge for health care providers
and countries providing national health care insurance. Further research into the eco-
nomic burden, including direct and indirect medical costs of AD in Taiwan, is there-
fore an important priority.
CONCLUSIONS
From 2000 through 2002, the direct medical costs of AD increased annually in
Taiwan among patients with AD aged ::0-60 years. No significant correlation was found
between increased total direct medical costs and sex or age. Results from this study
should be considered in reallocating limited medical resources for treating AD in
Taiwan.
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